https://doi.org/10.4081/aiua.2023.11350
Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction
Published: May 29, 2023
Abstract Views: 878
PDF: 484
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples’ relationship, and quality of life. [...]
Attia AA, Abdel-Hameed AKS, Amer MAEM, et al. Study of the prevalence and patterns of phosphodiesterase type 5 inhibitor use among sexually active Egyptian males: A National Cross-sectional Survey. Andrologia. 2019; 51:e13364.
DOI: https://doi.org/10.1111/and.13364
Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T. 2013; 38:407-19.
Atsbeha BW, Kebede BT, Birhanu BS, et al. The Weekend Drug; Recreational Use of Sildenafil Citrate and Concomitant Factors: A Cross-Sectional Study. Front Med (Lausanne). 2021; 8:665247.
DOI: https://doi.org/10.3389/fmed.2021.665247
Mulhall JP, Hassan TA, Rienow J. Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries. Int J Clin Pract. 2018; 72:e13074.
DOI: https://doi.org/10.1111/ijcp.13074
Cirillo L, Fusco GM, Di Bello F, et al. Sexual dysfunction: Time for a multidisciplinary approach? Arch Ital Urol Androl. 2023; 95:11236.
DOI: https://doi.org/10.4081/aiua.2023.11236
Bechara A, Casabé A, De Bonis W, et al. Recreational Use of Phosphodiesterase Type 5 Inhibitors by Healthy Young Men. J Sex Med. 2010;7:3736-42.
DOI: https://doi.org/10.1111/j.1743-6109.2010.01965.x
Korkes F, Costa-Matos A, Gasperini R, et al. Recreational Use of PDE5 Inhibitors by Young Healthy Men: Recognizing This Issue Among Medical Students. J Sex Med. 2008; 5:2414-2418.
DOI: https://doi.org/10.1111/j.1743-6109.2008.00792.x
Kimura M, Shimura S, Kobayashi H, et al. Profiling Characteristics of Men Who Use Phosphodiesterase Type 5 Inhibitors Based on Obtaining Patterns: Data from the Nationwide Japanese Population. J Sex Med 2012; 9:1649-1658.
DOI: https://doi.org/10.1111/j.1743-6109.2012.02728.x
Alshahrani S, Ahmed AF, Gabr AH, Al Ansari A, El-feky M, Elbadry MS. Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia. Arab Journal of Urology. 2016; 14:94-100.
DOI: https://doi.org/10.1016/j.aju.2016.03.003
Mirone V, Napolitano L, D’Emmanuele di Villa Bianca R, et al. A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation. Arch Ital Urol Androl. 2021; 93:221-226.
DOI: https://doi.org/10.4081/aiua.2021.2.221
Ahmed AF, Alshahrani S, Morgan A, et al. Demographics and sexual characteristics of sex-enhancing medication users: Study of a web-based cross-sectional sample of sexually active men. Arab Journal of Urology. 2017; 15:366-371.
DOI: https://doi.org/10.1016/j.aju.2017.09.003
Napolitano L, Fusco GM, Cirillo L, et al. Erectile dysfunction and mobile phone applications: Quality, content and adherence to European Association guidelines on male sexual dysfunction. Arch Ital Urol Androl. 2022; 94:211-216.
DOI: https://doi.org/10.4081/aiua.2022.2.211
Schnetzler G, Banks I, Kirby M, et al. Original Research—ED Pharmacotherapy: Characteristics, Behaviors, and Attitudes of Men Bypassing the Healthcare System When Obtaining Phosphodiesterase Type 5 Inhibitors. J Sex Med 2010; 7:1237-1246.
DOI: https://doi.org/10.1111/j.1743-6109.2009.01674.x
Harte CB, Meston CM. Recreational Use of Erectile Dysfunction Medications and Its Adverse Effects on Erectile Function in Young Healthy Men: The Mediating Role of Confidence in Erectile Ability. J Sex Med 2012; 9:1852-1859.
DOI: https://doi.org/10.1111/j.1743-6109.2012.02755.x
Napolitano L, Cirillo L, Fusco GM, et al. Natural treatments for erectile dysfunction: A focus on mobile health applications. Arch Ital Urol Androl. 2022; 94:373-374.
DOI: https://doi.org/10.4081/aiua.2022.3.373
How to Cite
Fusco, G. M., Cirillo, L., Mastrangelo, F., Romano, F., Di Mauro, E., Cacace, G., Spena, G., Iannicelli, A., Franzese, C. A., Mirone, V., La Rocca, R., & Napolitano, L. (2023). Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction. Archivio Italiano Di Urologia E Andrologia, 95(2). https://doi.org/10.4081/aiua.2023.11350
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.